# Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma

> **NCT00027508** · PHASE2 · TERMINATED · sponsor: **PharmaMar**

## Conditions studied

- Malignant Mesothelioma

## Interventions

- **DRUG:** trabectedin

## Key facts

- **NCT ID:** NCT00027508
- **Lead sponsor:** PharmaMar
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-07
- **Primary completion:** 2002-02
- **Final completion:** 2002-02
- **Target enrollment:** — (—)
- **Why stopped:** Enrolment halted prematurely and not resumed. 2 patients enrolled. No data was obtained.
- **Last updated:** 2015-02-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00027508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00027508, "Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00027508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*